Objective-Sex hormones may be critical determinants of ischemic heart disease and death in women, but results from previous studies are conflicting. To clarify this, we tested the hypothesis that extreme plasma concentrations of endogenous estradiol and testosterone are associated with risk of ischemic heart disease and death in women. Approach and Results-In a nested prospective cohort study, we measured plasma estradiol in 4600 and total testosterone in 4716 women not receiving oral contraceptives or hormonal replacement therapy from the 1981 to 1983 examination of the Copenhagen City Heart Study. During ≤30 years of follow-up, 1013 women developed ischemic heart disease and 2716 died. In women with a plasma estradiol below the fifth percentile compared with between the 10th and 89th percentiles, multifactorially adjusted risk of ischemic heart disease was 44% (95% confidence interval, 14%-81%) higher; however, plasma estradiol concentrations did not associate with death. Also, in women with a plasma testosterone concentration at or above the 95th percentile compared with between the 10th and 89th percentiles, multifactorially adjusted risk was 68% (34%-210%) higher for ischemic heart disease, 36% (18%-58%) higher for any death, and 38% (15%-65%) higher for death from other causes than cardiovascular disease and cancer. These results were similar for postmenopausal women alone. Conclusions-In women, extreme low concentrations of endogenous estradiol were associated with high risk of ischemic heart disease, and extreme high concentrations of endogenous testosterone were associated with high risk of ischemic heart disease and death. (Arterioscler Thromb Vasc Biol. 2015;35:471-477.
T he incidence of ischemic heart disease is lower in premenopausal than in postmenopausal women. Also, ischemic heart disease occurs in women at a later age than in men. Together this suggests that a low plasma concentration of estradiol and a low plasma estradiol:testosterone ratio may be an explanation for the increased risk of ischemic heart disease in postmenopausal women, 1 as both these measurements decreases around menopause. Although evidence from animal studies have suggested that both estradiol and testosterone have atheroprotective effects, randomized clinical intervention trials and a national study have in contrast reported an increased risk of ischemic heart disease in women using oral contraceptives or hormonal replacement therapy. Also, previous studies investigating the associations between endogenous sex hormones and ischemic heart disease are few and results are conflicting with reports of high risk in women with both low and high concentrations of endogenous estradiol and testosterone. [2] [3] [4] [5] The objectives of this study were as follow: first, to examine the associations between concentrations of endogenous plasma estradiol and testosterone and factors that may contribute to risk of ischemic heart disease and death, that is, age, total cholesterol, high-density lipoprotein cholesterol, body mass index, glucose, and systolic and diastolic blood pressure; second, to examine the associations between extreme plasma concentrations of estradiol and testosterone and risk of ischemic heart disease and death. For these purposes, we examined women from the 1981 to 1983 examination of the Copenhagen City Heart Study not receiving oral contraceptives or hormonal replacement therapy, and followed them prospectively for ≤30 years. To reduce bias introduced by physiologically low plasma estradiol concentrations in older
Results
In this nested cohort study, we included 4716 women from the 1981 to 1983 examination of the Copenhagen City Heart Study, which in total examined 12 698 individuals (7018 women and 5680 men) and is a prospective general population study, initiated in 1976 to 1978 with follow-up examinations in 1981 to 1983, 1991 to 1994, and 2001 to 2003. Among the 7018 women, plasma was available on 6023; however, as 247 women receiving oral contraceptives and 1060 receiving hormonal replacement therapy at baseline were excluded, plasma estradiol and testosterone measurements were available in 4600 and 4716 women for the present study. Baseline characteristics of these women are shown in the Table.
Plasma Estradiol and Testosterone
For plasma estradiol and testosterone concentrations, the median value was 445 pmol/L (interquartile range, 280-760; 95% confidence interval, 160-2170) in premenopausal and 150 pmol/L (120-180; 60-240) in postmenopausal women ( Figure 1 ). For plasma testosterone concentrations, the corresponding values were 1.9 nmol/L (1.6-2.3; 1.1-3.1) in premenopausal and 1.9 nmol/L (1.5-2.3; 1.1-3.1) in postmenopausal women. Plasma estradiol and testosterone concentrations were relatively high in both pre-and postmenopausal women and we therefore tested the reproducibility of the measurements using another immunoassay on a different autoanalyzer. R 2 for comparison between the 2 assays were R 2 =0.87 for estradiol (bias: 33.3 pmol/L) and R 2 =0.92 for testosterone (bias: −0.76 nmol/L; Figure I in the online-only Data Supplement).
A 10% lower plasma estradiol concentration was associated with slightly higher plasma total cholesterol (<0.001 mmol/L), plasma glucose (<0.001 mmol/L), and systolic and diastolic blood pressure (<0.001 mm Hg; Figure 2 ). Also, a 10% higher plasma testosterone concentration was associated with a 0.05year higher median age at menopause, a 0.02-mmol/L higher plasma total cholesterol, a 0.03-kg/m 2 higher body mass index, a 0.01-mmol/L higher plasma glucose, a 0.38-mm Hg higher systolic blood pressure, and a 0.19-mm Hg higher diastolic blood pressure.
Risk of Ischemic Heart Disease
For plasma estradiol concentrations, the multifactorially adjusted risk of ischemic heart disease was increased by 44% (95% confidence interval, 14%-81%) in women below the fifth percentile compared with women in the 10th to 89th percentiles; for estradiol:testosterone ratios, the corresponding risk was 61% (24%-208%; Figure 3 ). These values translate into a population attributable fraction for risk of ischemic 
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Women using hormonal replacement therapy or oral contraceptives were excluded. Continuous data are reported as median and interquartile range and categorical variables in percent. One unit alcohol corresponds to 12 g alcohol. HDL indicates high-density lipoprotein. heart disease of 1.6% (0.6%-2.2%) for plasma estradiol and of 1.9% (1.0%-2.6%) for the estradiol:testosterone ratio. Results were similar for postmenopausal women alone.
For plasma testosterone concentrations, the multifactorially adjusted risk of ischemic heart disease was increased by 68% (34%-210%) in women at or above the 95th percentile compared with women in the 10th to 89th percentiles ( Figure 3 ). This value translates into a population attributable fraction for risk of ischemic heart disease of 2.0% (1.3%-2.6%) for plasma testosterone. Results were similar for postmenopausal women alone.
Risk of ischemic heart disease was not higher in women with extreme high plasma concentrations of endogenous estradiol, extreme low plasma concentrations of testosterone, or in women with extreme high estradiol:testosterone ratios ( Figure 3 ).
Risk of Death
Plasma estradiol concentration did not associate with risk of death ( Figure 4 ). In contrast, for plasma testosterone concentrations the multifactorially adjusted risk of death was 36% (18%-58%) higher in women at or above the 95th percentile compared with women with a concentration in the 10th to 89th percentiles. This result translates into a population attributable fraction for risk of death of 1.3% (0.8%-1.8%) for plasma testosterone. Results were similar for postmenopausal women alone.
Plasma estradiol concentrations did not associate with risk of death from cardiovascular disease, cancer, breast cancer, or other causes ( Figure II in the Data Supplement). In contrast, for plasma testosterone concentrations, the multifactorially adjusted risk of death from other causes was 38% (15%-65%) higher in women at or above the 95th percentile when compared with women in the 10th to 89th percentiles. Also, for estradiol:testosterone ratios, the multifactorially adjusted risk of death from other causes was 23% (0%-52%) higher in women below the fifth percentile compared with women in the 10th to 89th percentiles.
Discussion
The main findings of this study of women are that extreme low plasma concentrations of endogenous estradiol were associated with high risk of ischemic heart disease, and that extreme high plasma concentrations of endogenous testosterone were associated with high risk of ischemic heart disease and death.
Major hormonal changes occur during menopause, including a profound fall in circulating estradiol concentrations of ovarian origin. 6 In cross-sectional studies, concentrations of total testosterone have been reported to be lower in postmenopausal compared with premenopausal women, 7, 8 whereas in longitudinal studies, either no change 9 or a 15% to 30% fall have been reported. 10, 11 In the present study of women from the general population, we observed the expected fall in estradiol coinciding with menopause, whereas testosterone concentrations were largely unchanged from the age of 20 to >80 years.
Median plasma estradiol and testosterone concentrations were in the present study relatively high in both pre-and postmenopausal women. The reason for this is unknown; however, all plasma samples were analyzed between 2009 and 2011 using the same immunoassays with a high accuracy; samples were only thawed once (freezing may reduce estradiol concentrations); a subset of samples reanalyzed in a different laboratory using other immunoassays on a different autoanalyzer showed a good reproducibility; and the physiological changes in estradiol levels during life were preserved in the samples. Importantly, as we have used percentiles generated within 10-year age groups, the relatively high median concentrations do not invalidate the results and conclusions of the present article, although they might limit the generalizability of our results to other populations.
Several studies have reported effects of estrogen and testosterone on cardiovascular risk factors. Low plasma estradiol concentrations have been generally associated with high concentrations of total cholesterol and low concentrations of high-density lipoprotein cholesterol. 1, 12 ; however, a recent study of women with ovarian failure and low estradiol concentrations also reported high total cholesterol and low-density lipoprotein cholesterol concentrations. 13 In the present study using percentiles of sex hormones generated in 10-year age groups and thus circumventing the age-dependent changes in sex hormones, we observed that low plasma concentrations of endogenous estradiol were associated with modest adverse effects on cardiovascular risk factors, and that high plasma concentrations of endogenous testosterone were associated with adverse effects on plasma total cholesterol, body mass index, plasma glucose, and blood pressure in women. This suggests that low estradiol is directly associated with cardiovascular risk, whereas the risk observed for high testosterone may be mediated through other cardiovascular risk factors.
Mechanistically our findings of risk of ischemic heart disease and death may be explained by multiple effects of sex hormones on the cardiovascular system. [14] [15] [16] [17] Thus, androgens including testosterone are precursors for estradiol biosynthesis 14 and estradiol and testosterone exert important actions in all body cells through interaction with estradiol and androgen receptors: binding of estradiol and testosterone to their receptors may either mediate a direct action on target cells, 18 may act as transcription factors, 19 or have other nongenomic actions in the cardiovascular system. 20 Indeed, both estradiol and testosterone have effects on endothelial cells, cardiovascular smooth muscle cells, myocardial fibers, macrophages, and platelets. [14] [15] [16] [17] Results from previous conventional epidemiological studies investigating the association between plasma concentrations of endogenous estradiol and testosterone and risk of ischemic heart disease are conflicting. [2] [3] [4] In the present study, we observed that extreme low, but not high plasma concentrations of endogenous estradiol were associated with higher risk of ischemic heart disease; and, as opposed to a previous study, 3 that extreme high, but not low plasma concentrations of endogenous testosterone were associated with high risk of ischemic heart disease. Strengthening the present findings, the risk was intermediate in women with a plasma estradiol in the fifth to ninth percentiles and a testosterone in the 90th to 94th percentiles, and even higher in women with a plasma estradiol below the fifth percentile and a plasma testosterone at or above the 95th percentile, suggesting a continuum of risks as function of low estradiol and high testosterone concentrations. To define thresholds at which the risk increases and to translate these thresholds into clinical relevant recommendations for risk prediction and potential treatment would require a large study or meta-analysis of large studies.
Population wise, the fraction of women at risk of ischemic heart disease and death because of extreme levels of endogenous sex hormones is small, and the proportion of risk potentially prevented by a normalization of plasma estradiol and testosterone concentrations is <2%. Also, the 44% higher risk of ischemic heart disease observed in women with a plasma estradiol below the fifth percentile compared with those in the 10th to 89th percentiles is relatively modest, taking into account that, for example, smoking is associated with a 65% higher risk of ischemic heart disease in the same population.
Early case-control studies and a meta-analysis of such studies suggested that hormone replacement with estrogen might reduce the risk of ischemic heart disease 21 ; however, subsequent randomized clinical intervention trials aiming to normalize low postmenopausal estradiol concentrations with exogenous conjugated equine estradiol resulted in an increase in cardiovascular events in the treated groups compared with placebo (HERS [The Heart and Estrogen/progestin Replacement Study] 22 and WHI [The Women's Health Initiative] 23 ). Not much is known about testosterone treatment and cardiovascular risk; however, post hoc and interim analyses of randomized clinical intervention trials have to date not reported increased risk of cardiovascular disease. [24] [25] [26] [27] In a recent national study of 1.6 million Danish premenopausal women aged 15 to 49 years followed up for 15-years, the use of oral contraceptives with 20 μg ethinyl estradiol was associated with a 1.5-fold increase in risk of myocardial infarction and 30 to 40 μg ethinyl estradiol with a 2-fold increase in risk 28 ; however, it is known that ethinyl estradiol has many cardiovascular effects, distinguishing it from other more natural types of estrogens and that the risk of cardiovascular disease is specifically observed for this synthetic preparation. 29 A known limitation of prospective studies using a single baseline measurement for classification is misclassification because of regression dilution bias because extreme values at baseline tend to attenuate over time, regress toward the mean value of measurements, cause an underestimation of the association between sex hormone and risk, and thus give more conservative risk estimates. For estradiol this may introduce a bias in premenopausal women where estradiol concentrations fluctuate during the menstrual cycle, cause random variation, and thus wider confidence intervals on risk estimates. For testosterone, a single measurement has been suggested to be fairly representative for the long-term hormonal milieu in men 30 ; however, little is known about estradiol and testosterone concentrations over time in women. As mentioned above, the median plasma concentrations of both estradiol and testosterone measured in the present study were relatively high and there was an ≈20% bias on plasma testosterone values >25 nmol/L between the 2 methods used, potentially limiting the generalizability of our results to other study populations. Another potential limitation of the present study is that we measured total testosterone, which includes the biologically active-free testosterone and testosterone bound to sex hormone binding globulin. It is not known how well the concentration of total testosterone correlates with the concentration of free testosterone, and whether the association of testosterone concentrations with risk of ischemic heart disease and death is because of high total or free testosterone concentrations. Furthermore, because testosterone can be aromatized to estradiol in endothelial cells, plasma concentrations of estradiol and testosterone provide only a partial indication of the potential concentrations at the target tissue. This variation in bioavailability may influence the strength of the associations of testosterone with other cardiovascular risk factors. Finally, it is a strength, as well as a potential limitation that we studied white women only; however, we are not aware of data to suggest that our results might not apply to women of all races.
In conclusion, in women, extreme low plasma concentrations of endogenous estradiol were associated with high risk of ischemic heart disease, and extreme high plasma concentrations of endogenous testosterone were associated with high risk of ischemic heart disease and death. These results suggest that the safety of testosterone supplementation resulting in extreme high testosterone concentrations in women might be a concern.
